BRIEF published on 08/04/2025 at 14:05, 9 months 8 days ago Medincell Annonce son Assemblée Générale 2025 Gouvernance Assemblée Générale Resolutions Medincell Rémunérations
PRESS RELEASE published on 08/04/2025 at 14:00, 9 months 8 days ago Informations privilégiées / Autres communiqués Medincell publie la convocation pour son assemblée générale annuelle mixte 2025, incluant des résolutions sur les comptes, l'approbation des dirigeants et des délégations au Conseil d'administration Assemblée Générale Convocation Resolutions Pharmaceutique Medincell
BRIEF published on 07/30/2025 at 14:34, 9 months 13 days ago Chiffre d'affaires croissant de Medincell et prochaines soumissions Traitement De La Schizophrénie Chiffre D'affaires De Medincell Ventes UZEDY Soumission D'olanzapine Partenariat Teva
BRIEF published on 07/30/2025 at 14:34, 9 months 13 days ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
PRESS RELEASE published on 07/30/2025 at 14:32, 9 months 13 days ago INFORMATIONS PRIVILÉGIÉES / AUTRES COMMUNIQUÉS Medincell accélère avec des prévisions de ventes 2025 relevées pour UZEDY® et confirmation de la demande de mise sur le marché américain pour l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 07/30/2025 at 14:29, 9 months 13 days ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 9 months 13 days ago Les prévisions de résultats financiers prometteurs pour les médicaments UZEDY® et Olanzapine LAI de Medincell Traitement De La Schizophrénie Teva Pharmaceuticals Prévisions De Revenus De Medincell Performances UZEDY® Développement De L'olanzapine LAI
BRIEF published on 07/30/2025 at 13:47, 9 months 13 days ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
PRESS RELEASE published on 07/30/2025 at 13:42, 9 months 13 days ago Inside Information / Other news releases Medincell's partner Teva increases 2025 revenue outlook for UZEDY® to $190–$200M, plans olanzapine LAI submission. Company's innovative treatments aim to improve medicine accessibility Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 07/30/2025 at 13:42, 9 months 13 days ago Informations privilégiées / Autres communiqués UZEDY® relève ses prévisions de ventes 2025 à 190–200 M$. Demande de mise sur le marché américain confirmée pour l'Olanzapine LAI en 2025. Medincell annonce les informations communiquées par Teva Pharmaceuticals Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Ventes 2025
Published on 05/12/2026 at 21:55, 1 hour 49 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 2 hours 2 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 14:30, 9 hours 14 minutes ago Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement
Published on 05/12/2026 at 14:30, 9 hours 14 minutes ago ACCESS Newswire Reports First Quarter 2026 Results
Published on 05/12/2026 at 22:25, 1 hour 18 minutes ago Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 3 hours 22 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 4 hours 9 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 4 hours 9 minutes ago 2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Published on 05/12/2026 at 18:46, 4 hours 57 minutes ago LION E-Mobility Reports Q1 Results and Confirms Fiscal 2026 Outlook
Published on 05/12/2026 at 18:15, 5 hours 29 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 5 hours 29 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 5 hours 34 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 5 hours 34 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 5 hours 54 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
